Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 7/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23970881 | 0.79 | GABRA1 (0.39) | LMNAGABRA1GABRB1CA1CA2 | |
| SCHEMBL18353218 | 0.79 | GABRA1 (0.39) | LMNAGABRA1GABRB1CA1CA2 | |
| SCHEMBL4648719 | 0.77 | GABRA1 (0.39) | LMNAGABRA1GABRB1SLC6A2CA1 | |
| SCHEMBL30164421 | 0.76 | LMNA (0.38) | LMNAGABRA1GABRB1SLC6A2HTR2B | |
| SCHEMBL24813077 | 0.76 | LMNA (0.38) | LMNAGABRA1GABRB1SLC6A2HTR2B | |
| SCHEMBL2737360 | 0.76 | GABRA1 (0.37) | LMNAGABRA1GABRB1CA1CA2 | |
| SCHEMBL12197721 | 0.76 | SLC6A2 (0.48) | LMNAGABRA1GABRB1SLC6A2HTR2B | |
| SCHEMBL13362528 | 0.76 | LMNA (0.44) | LMNAGABRA1GABRB1 | |
| SCHEMBL23510746 | 0.74 | LMNA (0.42) | LMNAGABRA1GABRB1SLC6A2HTR2B | |
| SCHEMBL23793797 | 0.74 | GABRA1 (0.35) | LMNAGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509479-B2 | P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-20240400592-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHAMACEUTICAL CO LTD (CN) | 2024-12-05 | — | — | US | disclosed |
| US-11919918-B2 | P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2024-03-05 | — | — | US | disclosed |
| EP-3712144-B1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2024-02-14 | — | — | EP | disclosed |
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2022-12-08 | — | — | US | disclosed |
| US-11414444-B2 | P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-08-16 | — | — | US | disclosed |
| US-20210179648-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3712144-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | disclosed |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-04-28 | — | — | US | disclosed |
| EP-2925743-B1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014184234-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179648-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | LMNA 1680/4885GABRA1 439/4885GABRB1 456/4885 |
| US-20240400592-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | LMNA 2224/4885GABRA1 266/4885GABRB1 251/4885 |
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | LMNA 691/4885GABRA1 2729/4885GABRB1 3064/4885 |
| US-20220389039-A1 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | P2RX3, P2RX2, P2RX7 | LMNA 2224/4885GABRA1 266/4885GABRB1 251/4885 |
| US-12509479-B2 | P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof | P2RX3, P2RX6, P2RX2 | LMNA 1339/4885GABRA1 303/4885GABRB1 257/4885 |
| US-11919918-B2 | P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof | P2RX3, P2RX2, P2RX1 | LMNA 2185/4885GABRA1 209/4885GABRB1 254/4885 |
| US-11414444-B2 | P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof | P2RX3, P2RX2, P2RX7 | LMNA 1680/4885GABRA1 439/4885GABRB1 456/4885 |
| US-20160115158-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100A4, S100B | LMNA 912/4885GABRA1 2958/4885GABRB1 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.